Announcement of transactions with shares and linked securities in H. Lundbeck A/S made by executives and their closely associated persons and legal entities


                        
H. Lundbeck A/S hereby reports transactions made by executives and persons and
legal entities closely associated to them with shares in H. Lundbeck A/S and
linked securities, cf. section 28a of the Danish Securities Trading Act.

The list is based on reports received by H. Lundbeck A/S from the company's
executives today or yesterday.


+-----------------------------------------+---------------------+
|Name:                                    |Egil Bodd            |
|                                         |                     |
+-----------------------------------------+---------------------+
|Job position of the executive:           |Board member         |
|                                         |                     |
+-----------------------------------------+---------------------+
|Relation to executive                    |                     |
|(associated person or legal entity):     |                     |
+-----------------------------------------+---------------------+
|ID code (ISIN code):                     |DK 0010287234        |
|                                         |                     |
+-----------------------------------------+---------------------+
|Description of the security:             |Share                |
|                                         |                     |
+-----------------------------------------+---------------------+
|Nature of the transaction:               |Sale of shares       |
|                                         |                     |
+-----------------------------------------+---------------------+
|Date of trading:                         |28 February 2011     |
|                                         |                     |
+-----------------------------------------+---------------------+
|Market on which the trading was effected:|Nasdaq OMX Copenhagen|
|                                         |                     |
+-----------------------------------------+---------------------+
|Number of traded securities:             |  8,000 Shares       |
|                                         |                     |
+-----------------------------------------+---------------------+
|Market price of securities traded:       |971,701 DKK          |
|                                         |                     |
+-----------------------------------------+---------------------+

Persons/entities under an obligation to report
Persons or entities under an obligation to report are defined as members of the
Executive Management and the Supervisory Board of H. Lundbeck A/S and
persons/entities closely associated to them.

Closely associated persons/entities means inter alia:

  * spouse or cohabitant

  * children below the age of 18

  * legal entities in which the insider has a controlling influence

The content of this release will have no influence on the Lundbeck Group's
financial expectations for 2011.


Lundbeck contacts


Investors:                           Media:



Palle Holm Olesen                    Mads Kronborg

Chief Specialist, Investor Relations Media Relations Manager

+45 36 43 24 26                      +45 36 43 28 51



Magnus Thorstholm Jensen             Stine Hove Marsling

Investor Relations Officer           External Communication Specialist

+45 36 43 38 16                      +45 36 43 28 33



Jacob Tolstrup

Vice President

+1 847 282 5713



About Lundbeck
H. Lundbeck A/S (LUN.CO, LUN DC, HLUKY) is an international pharmaceutical
company highly committed to improving the quality of life for people suffering
from central nervous system (CNS) disorders. For this purpose, Lundbeck is
engaged in the research, development, production, marketing and sale of
pharmaceuticals across the world. The company's products are targeted at
disorders such as depression and anxiety, schizophrenia, insomnia, epilepsy and
Huntington's, Alzheimer's and Parkinson's diseases.

Lundbeck was founded in 1915 by Hans Lundbeck in Copenhagen, Denmark. Today
Lundbeck employs approximately 5,900 people worldwide. Lundbeck is one of the
world's leading pharmaceutical companies working with CNS disorders. In 2010,
the company's revenue was DKK 14.8 billion (approximately EUR 2.0 billion or USD
2.6 billion). For more information, please visit www.lundbeck.com.

[HUG#1492978]

Subscribe

Documents & Links